#United States #Cambridge #Full Circles #CAR-T #genomic integration

Full Circles Therapeutics: A Leap Forward in Immune Cell Engineering

In a groundbreaking development in biotechnology, Full Circles Therapeutics, a leader in the creation of next-generation cell and gene therapies, announced the publication of an innovative study in the prestigious journal Nature Biotechnology. Underscoring its commitment to transforming healthcare, the study introduces a novel method of non-viral immune cell engineering that promises major improvements in therapeutic safety and cost-effectiveness.

The Innovative Approach

The paper titled "Efficient Non-Viral Immune Cell Engineering Using Circular Single-Stranded DNA-Mediated Genomic Integration" details a technique that utilizes circular single-stranded DNA (cssDNA) for precise genomic integration. This pioneering approach differs significantly from traditional methods that typically rely on viral vectors, which are often associated with safety concerns, inefficacy, and difficulties in large-scale production.

Dr. Howard (Hao) Wu, Chief Scientific Officer of Full Circles, stated, "We believe this non-viral method is a transformative advancement in the field." The new technology leverages the proprietary C4DNA system—a minicircle form of single-stranded DNA—to mediate stable genomic integration of engineered immune cells, including CAR-T and CAR-NK therapies. This innovation is considered essential for the development of off-the-shelf, ready-to-use therapies, poised to treat patients more rapidly and effectively.

Strong Patent Portfolio

Adding to the excitement surrounding this technological leap, Full Circles recently secured a foundational patent for the method in Japan, a key biopharmaceutical market, particularly concerning oncology, autoimmune diseases, and genetic disorders. The granted patent encompasses generic circular single-stranded DNA forms intended for targeted genome integration, which is showing encouraging results in preclinical trials.

This technology is not only expected to facilitate the next generation of cell and gene therapy but also aims to provide a reliable and adaptable non-viral solution. Dr. Richard Shan, Chairman and CEO, expressed his enthusiasm for the broad potential applications of this platform, which could address diseases that have historically resisted conventional treatment methods. "Our goal is to ensure that these therapies are accessible, affordable, and scalable, ultimately expediting their adoption in clinical settings," he remarked.

Recognition and Future Directions

Additionally, Full Circles has been awarded the Pathbreaker Award, sponsored by Novo Nordisk, reinforcing its commitment to driving groundbreaking treatments in partnership with other healthcare entities.

This collective advancement in research, patenting, and recognition signals a pivotal moment for Full Circles Therapeutics as it transforms the realm of cellular immunotherapy and gene therapy. As the company continues innovating, it seeks to make life-saving treatments more accessible to a larger patient population.

In conclusion, the publication of this study in Nature Biotechnology represents not just a milestone for Full Circles but a significant leap for the future of non-viral therapies in addressing critical health challenges. Those interested can access the study through Nature Biotechnology.

About Full Circles Therapeutics

Headquartered in Cambridge, MA, Full Circles Therapeutics is pioneering advancements in the frontier of therapeutic cell engineering, particularly focused on developing non-viral gene-editing technologies that prioritize safe, efficient, and scalable solutions for serious health conditions. Committed to expanding access to critical treatments, the company is reshaping the future landscape of immunotherapy and gene therapy.